Nonalcoholic fatty liver disease (WP4396)

Homo sapiens

Authors

Alex Pico and Egon Willighagen

Activity

Discuss this pathway

Check for ongoing discussions or start your own.

Cited In

• A Pilot Mitochondrial Genome-Wide Association on Migraine Among Saudi Arabians (2022).
• Coordinated Cross-Talk Between the Myc and Mlx Networks in Liver Regeneration and Neoplasia (2022).
• Target Deconvolution of Fenofibrate in Nonalcoholic Fatty Liver Disease Using Bioinformatics Analysis (2021).

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.

Organisms

Homo sapiens

Communities

Diseases

Annotations

Cell Type Ontology

hepatocyte

Disease Ontology

non-alcoholic fatty liver disease

Pathway Ontology

disease pathway liver disease pathway

References

1. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, et al. Gastroenterology. 2003 Aug;125(2):437–43. PubMed Europe PMC Scholia
2. Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat? Larter CZ, Farrell GC. J Hepatol. 2006 Feb;44(2):253–61. PubMed Europe PMC Scholia
3. Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases. Mantena SK, King AL, Andringa KK, Eccleston HB, Bailey SM. Free Radic Biol Med. 2008 Apr 1;44(7):1259–72. PubMed Europe PMC Scholia
4. Molecular mechanisms involved in NAFLD progression. Malaguarnera M, Di Rosa M, Nicoletti F, Malaguarnera L. J Mol Med (Berl). 2009 Jul;87(7):679–95. PubMed Europe PMC Scholia
5. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Hotamisligil GS. Cell. 2010 Mar 19;140(6):900–17. PubMed Europe PMC Scholia
6. Endoplasmic reticulum stress in liver disease. Malhi H, Kaufman RJ. J Hepatol. 2011 Apr;54(4):795–809. PubMed Europe PMC Scholia
7. NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications. Farrell GC, van Rooyen D, Gan L, Chitturi S. Gut Liver. 2012 Apr;6(2):149–71. PubMed Europe PMC Scholia
8. A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. Seki E, Brenner DA, Karin M. Gastroenterology. 2012 Aug;143(2):307–20. PubMed Europe PMC Scholia
9. Micro-RNA 21 inhibition of SMAD7 enhances fibrogenesis via leptin-mediated NADPH oxidase in experimental and human nonalcoholic steatohepatitis. Dattaroy D, Pourhoseini S, Das S, Alhasson F, Seth RK, Nagarkatti M, et al. Am J Physiol Gastrointest Liver Physiol. 2015 Feb 15;308(4):G298-312. PubMed Europe PMC Scholia
10. Role of FXR in Liver Inflammation during Nonalcoholic Steatohepatitis. Armstrong LE, Guo GL. Curr Pharmacol Rep. 2017 Apr;3(2):92–100. PubMed Europe PMC Scholia
11. Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells. Ji N, Yang Y, Cai CY, Lei ZN, Wang JQ, Gupta P, et al. Cancer Lett. 2019 Jan;440–441:82–93. PubMed Europe PMC Scholia